Navigation Links
B Vitamins Might Lower Stroke Risk
Date:2/19/2009

But jury is still out on their value, experts note

THURSDAY, Feb. 19 (HealthDay News) -- People with heart disease who take high doses of B vitamins are somewhat less likely to suffer from stroke, especially if they're under 70, a new Canadian study suggests.

But other studies have come to opposite conclusions about whether vitamins really protect against cerebrovascular disease, noted Dr. Larry B. Goldstein, director of the Duke Stroke Center at Duke University, in Durham, N.C.

"We will need to carefully review this study in light of these other reports," said Goldstein. "There remains no evidence that general vitamin supplementation lowers risk of stroke or other cardiovascular events, and considerable evidence that it is ineffectual."

The Canadian researchers sought to determine whether high doses of three B vitamins could dampen the risk of stroke by lowering levels of an amino acid known as homocysteine.

Some research has linked high levels of the amino acid in the blood to a higher risk of stroke, although there's a debate over what this means.

The American Heart Association has made a point of not declaring high homocysteine levels to be a risk factor for heart disease or stroke. In fact, the association doesn't recommend the widespread use of B vitamin supplements to counteract any risk.

In the new study, researchers from the University of Toronto and McMaster University examined the results of a research trial that randomly assigned 5,522 adults with heart disease to either take a daily regimen of several vitamins or placebo pills for five years.

The vitamin regimen included a daily dose of 2.5 milligrams of folic acid (a type of B vitamin), 50 milligrams of vitamin B6 and 1 milligram of vitamin B12. These levels are higher than people would normally get from their diets or from multivitamins, said Lona Sandon, spokeswoman for the American Dietetic Association.


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Vitamins Do Older Women Little Good
2. Many Kids Dont Need the Vitamins Theyre Taking
3. Nanotech in your vitamins
4. Metametrix Introduces the New Fat-Soluble Vitamins Profile - A Snapshot of Overall Nutrition
5. Vitamins Fail to Prevent Cancer: Study
6. Selenium, Vitamins E and C Wont Prevent Prostate Cancer
7. Changing Times Vitamins to Sponsor Emmanuel Manny Pacquiao in Upcoming Fight With Oscar De La Hoya.
8. ClutchWave LLC Launches PricePlow.com: Price Shopping For Supplements and Vitamins
9. King Features Syndicate and Changing Times Vitamins Sign Licensing Agreement for Popeye(R) the Sailor Man in the Water Drink Category.
10. Two Antioxidant Vitamins Dont Protect Against Heart Disease
11. Can Vitamins and Minerals Prevent Hearing Loss?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
B Vitamins Might Lower Stroke Risk
B Vitamins Might Lower Stroke Risk
Breaking Medicine Technology:Pharmacy Technician Employment Increasing Up to 32% By 2016 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti Infection Treatments 13413 1Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti Infection Treatments 13413 2Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti Infection Treatments 13413 3Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 1Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 2Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 3Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 4Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 5Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 6Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 7Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 8Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 9Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 10Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 11Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 12Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 13Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 14Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 15Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 16Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 17Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 18Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 19Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 20Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 21Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 22Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 23Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 24Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 25Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 26Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 27Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 28U S Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 53832 1U S Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 53832 2U S Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 53832 3